none act-1986-036 Drugs Misuse Act 1986 2026-05-01T00:00:00+10:00 sl-1987-dmr allinforce Administrator of the Government dmr reprint 2026-05-01 1987-10-31T00:00:00+10:00 website pp 836–47 0 reg Drugs Misuse Regulation 1987 1987 Drugs Misuse Regulation 1987 Part 1 Preliminary pt 1 hdg ins 1996 SL No. 309s 4 1 Short title This regulation may be cited as the Drugs Misuse Regulation 1987. 2 Dictionary The dictionary in schedule 9 defines particular words used in this regulation. s 2 prev s 2 amd 1996 SL No. 309s 5(1); om 8 November 1996 RA s 37 pres s 2 (prev s 4) sub 1998 SL No. 348s 3(2) renum 2002 No. 255s 3 s 2 def occupier’s notice reloc to sch 9 1998 SL No. 348s 3(1) s 2 def record of proceedings reloc to sch 9 1998 SL No. 348s 3(1) s 2 def search warrant reloc to sch 9 1998 SL No. 348s 3(1) s 2 def supply ins 1996 SL No. 309s 5(3) om 1998 SL No. 348s 3(2) s 2 def the Act sub 1989 reg pubd gaz 6 May 1989 pp 230–1 om 1996 SL No. 309s 5(2) Part 2 Syringes and dangerous drugs disposal procedures pt 2 hdg prev pt 2 hdg ins 1996 SL No. 309s 6 om 2002 SL No. 255s 4 pres pt 2 hdg (prev pt 3 hdg) ins 1996 SL No. 309s 11 renum 2002 SL No. 255s 5(1) 3 Prescribed procedures for the disposal of hypodermic syringes and needles For the purposes of section 10(4A) of the Act, the prescribed procedures for the disposal of a hypodermic syringe or needle are—

(a) by placing the hypodermic syringe or needle in a rigid wall, puncture resistant container and that container is sealed or securely closed in such a manner that its contents are incapable of causing injury to any person; or

(b) by giving the hypodermic syringe or needle to a person who is a medical practitioner, pharmacist or person or a member of a class of persons referred to as authorised in section 10(3) of the Act.

s 3 ins reg pubd gaz 6 May 1989 pp 230–1 renum 2002 SL No. 255s 5(2) amd 2009 SL No. 99s 3 4 Prescribed procedure for disposal of dangerous drugs For the purposes of section 125 of the Act, the prescribed procedure for the disposal of a thing is—

(a) in the case where the thing is a trace amount of a dangerous drug contained in a hypodermic syringe or needle, by disposing of the hypodermic syringe or needle in accordance with the procedures prescribed in section 3; or

(b) in any other case, at the first reasonable opportunity, by giving—

(i) such thing; and

(ii) where such thing is contained in a hypodermic syringe or needle, such syringe or needle;

to an inspector under the Medicines and Poisons Act 2019. s 4 (prev s 10) ins reg pubd gaz 6 May 1989 pp 230–1 renum 2002 SL No. 255s 5(2) amd 2006 SL No. 71s 4; 2008 Act No. 4s 34; 2009 SL No. 99s 4; amd 2021 SL No. 141s 93sch 8 Part 3 Controlled substances pt 3 hdg (prev pt 4 hdg) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(1) 5 Other act that is a relevant transaction—Act, s 43C(b) Any act by which a controlled substance is supplied by a person, in or in connection with the person’s business, to anyone else is a relevant transaction for the supply of a controlled substance. Example— A and B are partners in a chain of pharmacies. They make cold tablets to sell in the pharmacies by compounding ephedrine (a controlled substance) with other substances. The partners sell some of the left over ephedrine to a pharmaceutical research company and give the rest away. Both the sale and gift of ephedrine are relevant transactions. Editor’s note— Under section 43A of the Act— supply means give, distribute, sell or supply. s 5 prev s 5 amd 1996 SL No. 309s 7 om 2002 SL No. 255s 4 pres s 5 (prev s 11) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(2) 6 Documents and proof of identity required for supply of a controlled substance or controlled thing—Act, s 43D(1)(a) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (a recipient). (2) The person must, before supplying the substance or thing, obtain from the recipient a document (an end user declaration) showing the following information—

(a) the recipient’s name and address, and if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;

(b) details of the official document produced by the recipient under subsection (3) as evidence of the recipient’s identity;

(d) the name and quantity of the substance or thing to be supplied;

(e) if a thing is supplied—the serial number or unique identifier of the thing;

(f) the date on which the substance or thing is to be supplied;

(g) the purpose for which the substance or thing is to be supplied.

(3) If the recipient is an individual, the person must, before supplying the substance or thing, require the recipient to produce an official document containing the recipient’s photograph (for example, a passport or driver licence) as evidence of the recipient’s identity. (4) The person must, immediately the person supplies the substance or thing under the transaction, make an invoice for the supply of the substance or thing showing the following details—

(a) the recipient’s name and address;

(b) the recipient’s order number for the supply of the substance or thing;

(d) the name and quantity of the substance or thing supplied.

Maximum penalty for subsection (4)—20 penalty units. s 6 prev s 6 amd 1996 SL No. 309s 8 om 2002 SL No. 255s 4 pres s 6 (prev s 12) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(2) amd 2008 Act No. 4s 35; 2009 SL No. 99s 5 6A End user declaration to be given to commissioner of police service—Act, s 43D(1)(d) (1) This section applies to a person who supplies a controlled substance or controlled thing under a relevant transaction to anyone else (the recipient). (2) The person must, as soon as practicable after obtaining from the recipient the end user declaration mentioned in section 6(2), give a copy of the end user declaration to the commissioner of the police service. s 6A ins 2008 Act No. 4s 36 7 Details about supply of controlled substance or controlled thing to be recorded in register (1) The following details about a relevant transaction for the supply of a controlled substance or controlled thing must be recorded in the register—

(a) the name and address of the recipient and, if the recipient purports to obtain the substance or thing for another person, the other person’s name and address;

(b) the recipient’s order number for the supply of the substance or thing;

(d) if the recipient is—

(i) a company—its Australian Company Number; or

(ii) an individual—the type of official document produced under section 6(3) and the following details about the document—

(A) who issued it;

(B) its serial number or other identifying number or mark;

(e) the name and quantity of the substance or thing supplied;

(f) the date the substance or thing was supplied;

(g) the purpose for which the substance or thing was supplied.

(2) The details must be recorded in the register as soon as practicable, but in no case later than 7 days, after the day the person supplied the substance or thing under the transaction. (3) Nothing in this section prevents the keeping of a single register for the Act and another Act if—

(a) the keeping of the single register is not contrary to the other Act; and

(b) the details recorded under subsection (1) are easily identifiable in the single register.

Note— See section 43D(1)(c) of the Act for the requirement to keep the register. s 7 prev s 7 sub reg pubd gaz 17 December 1988 pp 2214–15 amd 1996 SL No. 309s 9 om 2002 SL No. 255s 4 pres s 7 (prev s 13) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(2) amd 2008 Act No. 4s 37; 2012 SL No. 92s 19 8 Details about loss or theft of controlled substance or controlled thing to be recorded in register The following details of the reporting to a police officer of the loss or theft of a controlled substance or controlled thing must be recorded in the register—

(a) the day and place the report was made;

(b) the name and registered number of the officer to whom the report was made;

s 8 prev s 8 om 1996 SL No. 309s 10 pres s 8 (prev s 14) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(2) amd 2008 Act No. 4s 38 9 Keeping of register, invoice and other documents (1) This section applies to the register and other documents mentioned in the Act, section 43D(1) and the invoice required under section 6(4). (2) A person who supplies a controlled substance or controlled thing under a relevant transaction must keep the register, documents or invoice—

(a) at the principal or only place in Queensland where the person engages in relevant transactions; and

(b) for 2 years from the day the person supplied the substance or thing under the transaction.

s 9 (prev s 15) ins 1996 SL No. 309s 12 renum 2002 SL No. 255s 5(2) amd 2008 Act No. 4s 39 Part 4 Commercial production of industrial cannabis pt 4 hdg (prev pt 5 hdg) ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 Division 1 Preliminary pt 4 div 1 hdg ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 10 Operation of pt 4 and schs 7 and 8 (1) Divisions 3 to 6 state activities stated persons are authorised to perform for the purposes of part 5B of the Act. (2) Schedule 7 states conditions applying to particular persons who perform activities stated in divisions 4, 5 and 6. (3) If a word used in this part, schedule 7 or schedule 8 is not defined in the dictionary but is defined for part 5B of the Act, the word has the same meaning as in that part, unless a contrary intention appears. Note— See section 46 of the Act for definitions for pt 5B of the Act. s 10 ins 2002 SL No. 255s 6 amd 2012 SL No. 92s 20; 2018 Act No. 5s 135 Division 2 Certified cannabis seed pt 4 div 2 hdg ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 11 Planting seed—Act, s 46, def planting seed (1) This section states, for section 46 of the Act, definition planting seed, when cannabis seed is taken to have been harvested from a cannabis plant (a 0.5% THC plant) with a THC concentration, in the plant’s leaves and flowering heads, of not more than 0.5%. (2) Cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if—

(a) both of the following apply—

(i) an authorised person, at the request of the licensee or on the authorised person’s own initiative, arranges for the THC concentration of a representative sample for the seed to be analysed;

(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and

(b) the seed is labelled with the required particulars. Note— See section 27C for additional labelling requirements.

(3) Also, cannabis seed originating in the State is taken to have been harvested from a 0.5% THC plant if—

(a) both of the following apply—

(i) an authorised person, at the request of the licensee or on the authorised person’s own initiative, authorises another person in writing to arrange for the THC concentration of a representative sample for the seed to be analysed in a NATA accredited laboratory;

(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and

(b) the seed is labelled with the required particulars. Note— See section 27C for additional labelling requirements.

(4) Cannabis seed originating in another State, or another country, is taken to have been harvested from a 0.5% THC plant if the recipient licensee—

(a) takes reasonable steps to confirm that—

(i) a representative sample for the seed has undergone an analysis that is substantially equivalent to an analysis mentioned in subsection (3)(a)(i); and

(ii) the results of the analysis state the THC concentration of the representative sample is not more than 0.5%; and

(b) labels the cannabis seed with the required particulars. Note— See section 27C for additional labelling requirements.

(5) In this section— authorised person means—

(a) an inspector; or

(b) another person authorised by the chief executive for the purpose of this section.

representative sample, for cannabis seed, means a representative sample of cannabis leaves and flowering heads taken from the crop from which the seed was harvested. s 11 ins 2002 SL No. 255s 6 sub 2018 Act No. 5s 136 Division 3 Carriers pt 4 div 3 hdg ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 12 Application of div 3 This division applies to a carrier only if the carrier is engaged or employed by any of the following to transport consigned cannabis—

(a) a researcher;

(b) a grower;

(d) an inspector;

(e) a seed supplier.

s 12 ins 2002 SL No. 255s 6 amd 2018 Act No. 5s 137 13 Supply (1) The carrier is authorised to transport consigned cannabis and give it to the person to whom it is consigned. (2) The authorisation—

(a) is for the time necessary for the carrier to transport the consigned cannabis and give it to the person to whom it is consigned; and

(b) has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment.

s 13 ins 2002 SL No. 255s 6 14 Possession (1) The carrier is authorised to possess consigned cannabis for the time necessary for the carrier to transport it to the person to whom it is consigned and give it to the person. (2) The authorisation has effect only while the carrier is acting in accordance with the terms of the carrier’s engagement or employment. s 14 ins 2002 SL No. 255s 6 Division 4 DPI researchers pt 4 div 4 hdg ins 2002 SL No. 255s 6 15 Supply A DPI researcher is authorised—

(a) to supply class A or class B research cannabis plants and seed to another DPI researcher or a researcher authorised to possess the cannabis plants and seed; and

(b) to supply class A and class B research cannabis seed to a grower for use, under the DPI researcher’s supervision, as part of a field trial the DPI researcher is conducting on land owned or leased by the grower; and

(i) a grower;

(ii) a researcher;

(iii) another DPI researcher;

(iv) a seed handler;

(v) the owner or operator of a facility where processed cannabis is, or is to be, used for manufacturing a manufactured product for sale by wholesale or retail; and

(d) to supply class A or class B research cannabis seed or industrial cannabis seed to a person in another State who is authorised under the law of that State to possess cannabis seed that, if grown, will produce plants with a THC concentration in their leaves and flowering heads that the person in the other State may possess; and

(e) to supply class A or class B research cannabis plants, industrial cannabis plants or processed cannabis to an analyst; and

(f) to supply processed cannabis to the owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail.

s 15 ins 2002 SL No. 255s 6 amd 2018 Act No. 5s 138 16 Production A DPI researcher is authorised to produce, for use in plant breeding programs for developing new commercial strains of industrial cannabis—

(a) industrial cannabis plants and seed; and

(b) class A and class B research cannabis plants and seed.

s 16 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 17 Possession A DPI researcher is authorised to possess any of the following for a purpose mentioned in section 15 or 16—

(a) industrial cannabis plants and seed;

(b) class A and class B research cannabis plants and seed;

s 17 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 Division 5 Inspectors pt 4 div 5 hdg ins 2002 SL No. 255s 6 18 Supply An inspector is authorised—

(a) to supply industrial cannabis plants, class A or class B research cannabis plants or processed cannabis to an analyst to analyse the THC concentration in any of them; and

(b) if the inspector is given industrial cannabis plants or seed or class A or class B research cannabis plants or seed for delivery to a particular person who is lawfully entitled to possess the plants or seed—to supply the plants or seed to the person.

s 18 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 19 Possession An inspector is authorised—

(a) to possess industrial cannabis plants, class A or class B research cannabis plants or processed cannabis given to the inspector for delivery to an analyst to analyse the THC concentration in the plants or processed cannabis; and

(b) to possess industrial cannabis plants or seed or class A or class B research cannabis plants or seed given to the inspector for delivery to a person lawfully entitled to possess the plants or seed.

s 19 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 Division 6 Other persons pt 4 div 6 hdg prev pt 4 div 6 hdg ins 2002 SL No. 255s 6 om 2018 Act No. 5s 139 pres pt 4 div 6 hdg (prev pt 4 div 7 hdg) ins 2002 SL No. 255s 6 renum 2018 Act No. 5s 147 20 Manufacturer The owner or operator of a facility where processed cannabis is used for manufacturing a manufactured product for sale by wholesale or retail is authorised to possess processed cannabis for using it for manufacturing a manufactured product. s 20 prev s 20 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 om 2018 Act No. 5s 139 pres s 20 (prev s 23) ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 renum 2018 Act No. 5s 149 21 Analyst (1) An analyst is authorised to possess—

(a) standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration; and

(b) if an authorised person engages or employs the analyst to analyse a substance to determine its THC concentration—the substance for the purpose of the analysis.

(2) In this section— authorised person means any of the following—

(a) a researcher;

(b) a grower;

(d) an inspector.

substance means a substance that an authorised person reasonably believes to be any of the following—

(a) industrial cannabis plants;

(b) class A or class B research cannabis plants;

s 21 prev s 21 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 om 2018 Act No. 5s 139 pres s 21 (prev s 24) ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 amd 2018 Act No. 5s 141 renum 2018 Act No. 5s 149 22 Family members (1) A person who is a member of the immediate family of a licensee is authorised to produce, possess or supply a substance if—

(a) the licensee is authorised to produce, possess or supply the substance under the Act; and

(b) the person’s production, possession or supply of the substance is necessary for, or incidental to the licensee’s production, possession or supply of the substance.

(2) In this section— substance means any of the following—

(a) class A research cannabis plants;

(b) class A research cannabis seed;

(d) class B research cannabis seed;

(e) industrial cannabis plants;

(f) industrial cannabis seed;

(g) processed cannabis.

s 22 prev s 22 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 om 2018 Act No. 5s 140 pres s 22 (prev s 25) ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 renum 2018 Act No. 5s 149 23 Employees of authorised persons (1) An employee of an authorised person is authorised to produce, possess, supply or transport a substance if—

(a) under the Act, the authorised person is authorised to produce, possess, supply or transport the substance; and

(b) the employee’s production, possession, supply or transportation of the substance is necessary for, or incidental to, performing the employee’s employment or engagement.

(2) In this section— authorised person means any of the following—

(a) a licensee;

(b) a carrier;

(d) an inspector;

(e) a manufacturer;

(f) an analyst.

employee includes agent. substance means any of the following—

(a) class A research cannabis plant;

(b) class A research cannabis seed;

(d) class B research cannabis seed;

(e) industrial cannabis plant;

(f) industrial cannabis seed;

(g) processed cannabis.

s 23 (prev s 26) ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 amd 2018 Act No. 5s 142 renum 2018 Act No. 5s 149 Division 7 Record requirements pt 4 div 7 hdg (prev pt 4 div 7A hdg) ins 2018 Act No. 5s 132 renum 2018 Act No. 5s 147 24 Record requirements—Act, s 110E This division prescribes, for section 110E of the Act, record requirements for the holder of a relevant authority. s 24 (prev s 26A) ins 2018 Act No. 5s 132 renum 2018 Act No. 5s 149 25 Recording information—researchers and growers (1) A licensee, who is a researcher or a grower, must make a written record of each of the following—

(a) the strains or varieties of all cannabis seed in the licensee’s possession;

(b) the strains or varieties of all cannabis plants the licensee is growing;

(d) if the licensee is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11(4)(a)(ii);

(e) when and by whom cannabis plants or seed were delivered to the licensee;

(f) if cannabis plants or seed is delivered to the licensee by a carrier—the name of the individual who actually delivered the plants or seed;

(g) if the licensee supplies cannabis plants or seed to a carrier for delivery to a person—

(i) the name of the individual to whom the plants or seed were given for delivery; and

(ii) the name of the person to whom it is intended the plants or seed be supplied by the licensee;

(h) when cannabis seed is planted by the licensee;

(i) if the licensee supplies cannabis plants or seed to another person (the recipient) who is authorised to possess the cannabis plants or seed—

(i) the name of the recipient; and

(ii) what the recipient intends to use the cannabis plants or seed for; and

(iii) for cannabis plants or seed that is not processed cannabis—particulars of how the cannabis plants or seed was grown, or otherwise obtained, by the licensee; and

(iv) the date on which the cannabis plants or seed was supplied to the recipient; and

(v) the quantity of cannabis plants or seed supplied to the recipient;

(j) if the licensee disposes of or destroys cannabis plants or seed—

(i) the date the cannabis plants or seed is disposed of or destroyed; and

(ii) the method the licensee used to dispose of or destroy the cannabis plants or seed.

(2) The licensee must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the licensee. s 25 (prev s 26B) ins 2018 Act No. 5s 132 amd 2018 Act No. 5s 143 renum 2018 Act No. 5s 149 26 Recording information—seed handlers (1) A seed handler must make a written record of each of the following—

(a) the source and quantity of all industrial cannabis seed supplied to the seed handler;

(b) when and by whom industrial cannabis seed was delivered to the seed handler;

(c) if industrial cannabis seed is delivered to the seed handler by a carrier—the name of the individual who actually delivered the seed;

(d) if the seed handler is the first licensee to take possession of planting seed after the seed enters the State—a report number, or other identifying information, for the report containing the results mentioned in section 11(4)(a)(ii);

(e) if the industrial cannabis is denatured by the seed handler—how, when and by whom the industrial cannabis seed was denatured;

(f) if the seed handler supplies industrial cannabis seed to a carrier for delivery to a person—

(i) the name of the person to whom the seed was given for delivery; and

(ii) the name of the person to whom it is intended the seed be supplied by the seed handler;

(g) the name of each person to whom the seed handler supplies industrial cannabis seed.

(2) The seed handler must make the record of the information as soon as practicable, but no later than 7 days, after the information becomes available to the seed handler. s 26 (prev s 26C) ins 2018 Act No. 5s 132 amd 2018 Act No. 5s 144 renum 2018 Act No. 5s 149 26D s 26D ins 2018 Act No. 5s 132 om 2018 Act No. 5s 145 27 Keeping record of information (1) A holder of a relevant authority must keep the record of the information until the end of the first of the following periods—

(a) if the authority ends—3 years after the authority ends;

(b) if the holder stops being the holder of the authority—2 years after the holder stops being the holder of the authority.

(2) The holder must keep the record in a form that is readily accessible, usable and able to be interpreted. s 27 prev s 27 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 om 2018 Act No. 5s 148 pres s 27 (prev s 26E) ins 2018 Act No. 5s 132 renum 2018 Act No. 5s 149 Division 7A Notification requirements pt 4 div 7A hdg (prev pt 4 div 7B hdg) ins 2018 Act No. 5s 132 renum 2018 Act No. 5s 147 27A Notification requirements—researchers and growers (1) This section prescribes, for section 110F of the Act, notification requirements for a licensee who is a researcher or a grower. (2) The licensee must give an inspector written notice—

(a) of the planting of cannabis seed by the licensee; and

(b) if cannabis plants planted by the licensee will not be harvested—of the following—

(i) the plants will not be harvested;

(ii) how the licensee will dispose of or destroy the plants; and

(c) in relation to a crop of industrial cannabis or class B research cannabis plants planted by the licensee—that the crop is ready to be tested for THC concentration.

(3) The licensee must give a notice under this section to an inspector—

(a) for a notice mentioned in subsection (2)(a)—within 14 days of the planting of the seed; or

(b) for a notice mentioned in subsection (2)(b)—within 3 months of the planting of the cannabis plants; or

s 27A (prev s 26F) ins 2018 Act No. 5s 132 amd 2018 Act No. 5s 146 renum 2018 Act No. 5s 149 Division 8 Other provisions pt 4 div 8 hdg ins 2002 SL No. 255s 6 27B Prescribed information for research plans—Act, s 54 (1) This section prescribes, for section 54(2)(d) of the Act, information that must be included in a research plan relating to an application for a researcher licence. (2) The research plan must—

(a) describe the research and associated activities proposed to be carried out under the licence; and

(b) describe the location of all places where the research and associated activities will be carried out; and

(d) describe measures proposed to be implemented to manage all risks mentioned in paragraph (c), including, for example—

(i) how the following will be secured—

(A) cannabis crops, cannabis seed and equipment associated with the research and associated activities;

(B) information and records associated with the research and associated activities; and

(ii) what security screening protocols will be put in place for the employees, or other persons, dealing with cannabis crops, cannabis seed and equipment associated with the research and associated activities; and

(iii) how the researcher will restrict access, of employees or other persons, to cannabis crops, cannabis seed and equipment associated with the research and associated activities; and

(iv) how cannabis crops, cannabis seed and equipment associated with the research and associated activities will be safely and securely stored, handled or transported; and

(e) contain any additional information stated in a guideline published by the chief executive under subsection (3).

(3) For subsection (2)(e), the chief executive may publish, on the department’s website, a guideline stating additional information that the chief executive reasonably considers is relevant for the management of risks associated with research and associated activities carried out under a researcher licence. s 27B ins 2018 Act No. 5s 150 27C Labelling method (1) This section applies if a provision of this part, or a condition of a licence, requires—

(a) cannabis seed to be labelled so as to indicate particular information; or

(b) particular information to otherwise be included on a container, however described, of cannabis seed.

(2) The requirement is complied with only if the information is—

(a) either—

(i) written or stamped on—

(A) the outside of the container in a position where the information can be clearly seen on the container; or

(B) a label that is fixed to the outside of the container in a position where the label can be clearly seen on the container; or

(ii) if, because the seed is being supplied in bulk, subparagraph (i) cannot reasonably be complied with—included in a written notice given to a person to whom the seed is supplied before or when the seed is delivered to the person; and

(b) written in English; and

(d) written in characters that are either—

(i) dark print on a light background; or

(ii) light print on dark background.

(3) A notice under subsection (2)(a)(ii) may be fixed to, or form part of, a delivery docket or invoice given to the person to whom the seed is supplied. s 27C ins 2018 Act No. 5s 150 28 Fees The fees payable under the Act are stated in section 28A and schedule 8E. s 28 ins 1998 SL No. 348s 4 sub 2002 SL No. 255s 6 amd 2004 SL No. 231s 14; 2005 SL No. 268s 14; 2006 SL No. 267s 14; 2007 SL No. 232s 14; 2008 SL No. 314s 14; 2009 SL No. 176s 17; 2010 SL No. 268s 7; 2011 SL No. 110s 14; 2012 SL No. 92s 21; 2013 SL No. 102s 16; 2014 SL No. 113s 16; 2015 SL No. 57s 16; 2016 SL No. 99s 14; 2017 SL No. 111s 16; 2018 SL No. 98s 16; 2019 SL No. 127s 17 sub 2020 SL No. 152s 15; 2021 SL No. 85s 16; 2022 SL No. 6s 3 28A Monitoring fees—Act, s 110G (1) For section 110G(1) of the Act, the monitoring fee for the monitoring of activities performed under a relevant authority is provided for in this section and schedule 8E, item 8. (2) The fee stated in schedule 8E, item 8 may consist of, or include, an amount for part of an hour that is the equivalent of the relevant proportion of the hourly rate, stated in the schedule, worked out using 15-minute periods (wholly or partly completed). (3) In addition to the monitoring fee stated in schedule 8E, item 8, the holder of the relevant authority must pay—

(a) the fee worked out under subsection (4) for an inspector monitoring the activities to travel between the inspector’s usual place of work and the place where the activities are monitored; and

(b) if, for monitoring the activities, an inspector takes a sample of cannabis for analysis to determine the THC concentration of the sample—the reasonable cost of analysing the sample.

(4) For subsection (3)(a), the fee must be worked out at the rate stated in schedule 8E, item 8 for the time taken for the travel up to a maximum of 2 hours in a day. s 28A ins 2022 SL No. 6s 3 amd 2022 SL No. 52s 16 29 Licence conditions—Act, s 64 (1) The conditions in schedule 8 are prescribed for section 64(3) of the Act. (2) Unless otherwise expressly stated, the conditions apply to all licensees. s 29 ins 2001 SL No. 52s 3 sub 2002 SL No. 255s 6 Part 5 Transitional provisions pt 5 hdg (prev pt 6 hdg) ins 2001 SL No. 174s 3 renum 2002 SL No. 255s 5(1) amd 2002 SL No. 368s 3 30 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2001 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of the Drugs Misuse Amendment Regulation (No. 2) 2001 (the amending regulation), continues to apply in relation to an offence against the Act committed before the commencement of the amending regulation. (2) Proceedings for an offence against the Act committed before the commencement of the amending regulation may be continued or started as if the amending regulation had not been made. s 30 ins 2001 SL No. 174s 3 31 Transitional provision for Drugs Misuse Amendment Regulation (No. 2) 2002 (1) To remove doubt, it is declared that this regulation, as in force immediately before the commencement of this section, continues to apply in relation to an offence against the Act committed before the commencement of this section. (2) Proceedings for an offence against the Act committed before the commencement of this section may be continued or started as if the Drugs Misuse Amendment Regulation (No. 2) 2002 had not been made. s 31 ins 2002 SL No. 368s 4 Schedule 1 Dangerous drugs sections 4, definition dangerous drug, 4A, 5, 6, 8, 8A, 9 and 134 of the Act sch 1 amd reg pubd gaz 17 December 1988 pp 2214–5 om 1996 SL No. 309s 13 Part 1 Non-steroid drugs

Amphetamine

Cocaine

Heroin

Lysergide

Methylamphetamine

3,4-Methylenedioxymethamphetamine (MDMA)

Paramethoxyamphetamine (PMA)

Paramethoxymethamphetamine (PMMA)

Phencyclidine

Part 2 Steroid drugs

Androisoxazole

Androstenediol

Atamestane

Bolandiol

Bolasterone

Bolazine

Boldenone (dehydrotestosterone)

Bolenol

Bolmantalate

Calusterone

Chlorandrostenolone

4-Chloromethandienone

Chloroxydienone

Chloroxymesterone (dehydrochloromethyltestosterone)

Clostebol (4-chlorotestosterone)

Danazol

Dehydroepiandrosterone (DHEA)

Dihydrolone

Dimethandrostanolone

Drostanolone

Enestebol

Epitiostanol

Ethyldienolone

Ethylestrenol

Fluoxymesterone

Formebolone (formyldienolone)

Furazabol

4-Hydroxy-19-nortestosterone

Hydroxystenozol

Mebolazine

Mepitiostane

Mesabolone

Mestanolone (androstalone)

Mesterolone

Methandienone

Methandriol

Methenolone

Methylclostebol

Methyltestosterone

Methyltrienolone

Metribolone

Mibolerone

Nandrolone

Norandrostenolone

Norbolethone

Norclostebol

Norethandrolone

Normethandrone

Ovandrotone

Oxabolone

Oxandrolone

Oxymesterone

Oxymetholone

Prasterone

Propetandrol

Quinbolone

Silandrone

Stanolone

Stanozolol

Stenbolone

Testosterone, other than in implant preparations for growth promotion in animals

Thiomesterone (tiomesterone)

Tibolone

Trenbolone (trienbolone, trienolone), other than in implant preparations for use in animals

Trestolone

Any other anabolic and androgenic steroidal agent

sch 1 (prev 1986 Act No. 36sch 1) amd 1996 Act No. 49s 15 reloc 1996 Act No. 49s 21 amd 1997 SL No. 459s 3; 2001 SL No. 174s 4; 2002 SL No. 255s 7(1); 2008 Act No. 4s 40; 2009 SL No. 99s 6; 2013 SL No. 41s 3; 2014 Act No. 42 ss 23, 24 Schedule 2 Dangerous drugs sections 4, definition dangerous drug, 4A, 5, 6, 8, 8A, 9 and 134 of the Act

Acetorphine

4-Acetoxy-N,N-diethyltryptamine (4-AcO-DET)

4-Acetoxy-N,N-dimethyltryptamine (O-Acetylpsilocin)

Acetyl-alpha-methylfentanyl

N-Acetyl-4-bromo-2,5-dimethoxyphenethylamine (N-Acetyl 2C-B)

Acetyldihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of acetyldihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of acetyldihydrocodeine.

Acetylmethadol

Acetylmorphine

N-(1-Adamantyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (FUB AKB48)

N-(1-Adamantyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AKB48)

N-(1-Adamantyl)-1-pentyl-indazole-3-carboxamide (APINACA or AKB48)

Adamantyl 1-pentyl-indazole-3-carboxylate (APINAC or AKB57)

N-(1-Adamantyl)-1-pentyl-indole-3-carboxamide (SDB-001)

Alfentanil

Alkoxyamphetamines and bromo-substituted alkoxyamphetamines other than where separately specified

Alkoxyphenethylamines and alkyl-substituted alkoxyphenethylamines other than where separately specified

Alkylthioamphetamines and substituted alkylthioamphetamines other than where separately specified

Allobarbital

Allylprodine

Alphacetylmethadol

Alpha-Ethylaminopentiophenone (alpha-EAPP)

Alphaethyltryptamine

Alphameprodine

Alphamethadol

Alpha-Methylfentanyl

Alpha-Methylthiofentanyl

Alphamethyltryptamine (AMT)

Alphaprodine

Alpha-Pyrrolidinoheptanophenone (PV8)

Alpha-Pyrrolidinohexanophenone (alpha-PHP)

Alpha-Pyrrolidinovalerophenone (alpha-PVP)

Alphenal

Alprazolam

2-Aminoindane

N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indazole-3-carboxamide (PX-2)

N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-fluoropentyl)-indole-3-carboxamide (PX-1)

4-Amino-3-phenylbutanoic acid (Phenibut)

6-(2-Aminopropyl)benzofuran (6-APB)

5-(2-Aminopropyl)-2,3-dihydrobenzofuran (5-APDB)

6-(2-Aminopropyl)-2,3-dihydrobenzofuran (6-APDB)

Aminorex

Amobarbital

Anileridine

Aprobarbital

Bambuterol

Barbital

Barbituric acid and any 5,5 disubstituted derivatives of barbituric acid, whether or not further substituted at position 1 of the ring

Benzethidine

Benzphetamine (N-Benzyl-N-alpha-dimethylphenethylamine)

Benzylmorphine

N-Benzylpiperazine (BZP)

Betacetylmethadol

Beta-Hydroxy-3-methylfentanyl

Beta-Hydroxyfentanyl

Betameprodine

Betamethadol

Betaprodine

Bezitramide

Bromazepam

4-Bromo-2,5-dimethoxyamphetamine (DOB, 4-Bromo-DMA)

4-Bromo-2,5-dimethoxyphenethylamine (2C-B)

Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b’]difuran-4-yl)-2-aminopropane)

2-Bromomethcathinone

3-Bromomethcathinone

4-Bromomethcathinone

Brotizolam

Bufotenine (5-Hydroxy-N,N-dimethyltryptamine)

Buprenorphine

Butabarbital

Butalbital

Butallylonal

Butethal

Butonitazene

Butorphanol

1-Butyl-3-(2-methoxybenzoyl)indole (RCS-4(C4) 2-methoxy isomer)

1-Butyl-3-(1-naphthoyl)indole (JWH-073)

Camazepam

Cannabinoids other than tetrahydrocannibinols

Cannabis

N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (ADB CHMICA)

N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (ADB FUBINACA)

N-(1-Carbamoyl-2,2-dimethylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ADBICA)

N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indazole-3-carboxamide (AB CHMINACA)

N-(1-Carbamoyl-2-methylpropyl)-1-(cyclohexylmethyl)-indole-3-carboxamide (AB CHMICA)

N-(1-Carbamoyl-2-methylpropyl)-1-(4-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA)

N-(1-Carbamoyl-2-methylpropyl)-1-(2-fluorobenzyl)-indazole-3-carboxamide (AB FUBINACA 2-fluorobenzyl isomer)

N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indazole-3-carboxamide (5-Fluoro AB PINACA)

N-(1-Carbamoyl-2-methylpropyl)-1-(5-fluoropentyl)-indole-3-carboxamide (5-Fluoro ABICA)

N-(1-Carbamoyl-2-methylpropyl)-1-pentyl-indazole-3-carboxamide (AB PINACA)

[3-(3-Carbamoylphenyl)phenyl] N-cyclohexylcarbamate (URB-597)

Carfentanil

Catha edulis (Khat)

Cathine

Cathinone

Chlordiazepoxide

4-Chloroamphetamine

4-Chloro-2,5-dimethoxyamphetamine (DOC)

2-Chloromethcathinone

3-Chloromethcathinone

4-Chloromethcathinone

1-(5-Chloropentyl)-3-(1-naphthoyl)indole (5-Chloro JWH-018)

Chlorphentermine (4-chloro-alpha,alpha-dimethylphenethylamine)

Clenbuterol

Clobazam

Clonazepam

Clonitazene

Clorazepate

Clotiazepam

Cloxazolam

Coca leaf

Codeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 30mg or less of codeine per dosage unit; or

(b) in undivided preparations containing 1% or less of codeine.

Codeine-N-Oxide

Codoxime

N-Cumyl-1-(5-fluoropentyl)-7-azaindole-3-carboxamide (CUMYL-5F-P7AICA)

N-Cumyl-1-(5-fluoropentyl)-indazole-3-carboxamide (CUMYL-5F-PINACA)

N-Cumyl-1-pentyl-indazole-3-carboxamide (CUMYL-PINACA)

4-Cyano-2-dimethylamino-4,4-diphenylbutane

4-Cyano-1-methyl-4-phenylpiperidine

Cyclobarbital

Cyclohexyl [1,1'-biphenyl]-3-ylcarbamate (URB-602)

1-Cyclohexyl-4-(1,2-diphenylethyl)-piperazine (MT-45)

1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole (RCS-8)

1-(Cyclohexylmethyl)-3-(4-methoxy-1-naphthoyl)indole (CHM-081)

Cyclopal

Delorazepam

Desomorphine

Desoxypipradrol (2-DPMP)

Dextromoramide

Dextropropoxyphene

Diampromide

Diazepam

3,4-Dichloro-N-2-(dimethylamino)cyclohexyl-N-methylbenzamide (U-47700)

Diethylpropion

Diethylthiambutene

N,N-Diethyltryptamine

Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Dihydroetorphine

Dihydromorphine

Dimenoxadol

Dimepheptanol

Dimethocaine

2,5-Dimethoxyamphetamine (2,5-DMA)

2,5-Dimethoxy-4-ethylamphetamine (DOET)

2,5-Dimethoxy-4-ethylphenethylamine (2C-E)

2,5-Dimethoxy-4-ethylthiophenethylamine (2C-T-2)

2,5-Dimethoxy-4-iodoamphetamine (DOI)

2,5-Dimethoxy-4-methylamphetamine (DOM)

2,5-Dimethoxy-4-propylphenethylamine (2C-P)

2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7)

Dimethylamino-1,2-diphenylethane

2-Dimethylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Dibutylone)

N,N-Dimethylamphetamine

1,3-Dimethylamylamine (DMAA or methylhexanamine)

3-(1,2-Dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6-H-dibenzo(b,d)pyran

1,1-Dimethylheptyl-11-hydroxytetrahydrocannabinol (HU-210)

N,N-Dimethyl-3,4-methylenedioxyamphetamine (MDDM)

5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP 47, 497 C8 homologue)

Dimethylthiambutene

N,N-Dimethyltryptamine

Dioxaphetyl butyrate

Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Dipipanone

Drotebanol

Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine

Ephedra spp.

Ephedrine

Erythropoietin (EPO)

Erythroxylum coca

Erythroxylum nova-granatense

Estazolam

Ethchlorvynol

Ethinamate

4-Ethoxyamphetamine

4-Ethoxy-2,5-dimethoxyamphetamine (MEM)

N-Ethylamphetamine

Ethylcathinone (2-ethylamino-1-phenyl-propan-1-one)

Ethyl Loflazepate

Ethylmethylthiambutene

Ethylmorphine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of ethylmorphine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of ethylmorphine.

N-Ethyl-1-phencyclohexylamine

Ethylphenidate

Ethyl 1-(phenylacetyl)-L-prolylglycinate (GVS-111)

Etizolam

Etodesnitazene (Etazene)

Etonitazene

Etonitazepipne

Etonitazepyne

Etorphine

Etoxeridine

Etryptamine

Fencamfamin

Fenethylline (Theophylline-ethylamphetamine)

Fenoterol

Fenproporex (N-2-Cyanoethylamphetamine)

Fentanyl

Flubromazepam

Flubromazolam

Fludiazepam

Flunitazene

Flunitrazepam

2-Fluoroamphetamine

3-Fluoroamphetamine

4-Fluoroamphetamine

(1-(4-Fluorobenzyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (FUB-144)

2-Fluoromethamphetamine

3-Fluoromethamphetamine

4-Fluoromethamphetamine

2-Fluoromethcathinone

3-Fluoromethcathinone

4-Fluoromethcathinone

1-(5-Fluoropentyl)-3-(1-adamantylamido)indole (STS-135)

(1-(5-Fluoropentyl)-1-benzo[d]imidazol-2-yl)(naphthalen-1-yl)methanone (FUBIMINA)

1-(5-Fluoropentyl)-3-(4-ethyl-1-naphthoyl)indole (EAM-2201)

1-(5-Fluoropentyl)-3-(4-fluoro-1-naphthoyl)indole (FAM-2201)

(1-(5-Fluoropentyl)-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl) methanone (XLR-11; 5-Fluoro UR-144)

1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM-694)

1-(5-Fluoropentyl)-3-(4-methyl-1-naphthoyl)indole

(5-Fluoro JWH-122)

1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole (THJ-2201)

1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM-2201)

1-(5-Fluoropentyl)-N-(phenylmethyl)-1-indole-3-carboxamide (5-Fluoro SDB-006)

1-(p-Fluoro)phenylpiperazine

Flurazepam

Formoterol other than in metered aerosols for inhalation

Furethidine

Gamma hydroxybutyric acid (GHB)

Glutethimide

Growth Hormone (hGH)

Halazepam

Haloxazolam

Harmaline

Harmalol

Heptabarbital

Hexethal

Hexobarbital

1-Hexyl-3-(1-naphthoyl)indole (JWH-019)

Hydrocodone

Hydromorphinol

Hydromorphone

2-[(1R,3S)-3-Hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol (CP 47,497)

4-Hydroxy-N,N-diethyltryptamine (4-HO-DET)

N-(2-Hydroxyethyl)-alpha-methylbenzeneethanamine

N-Hydroxy-3,4-methylenedioxyamphetamine (N-Hydroxy-MDA)

4-Hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET)

4-Hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MIPT)

Hydroxypethidine

5-Hydroxy tryptophan (5-HTP) other than in preparations containing 100mg or less of 5-HTP per dosage unit

Insulin-like Growth Factor-1 (IGF-1)

4-Iodo-2,5-dimethoxyphenethylamine (2C-I)

Isomethadone

Isotonitazene

Ketamine

Ketazolam

Ketobemidone

Lefetamine (N,N-Dimethyl-alpha-phenylphenethylamine)

Levomethorphan

Levophenacylmorphan

Levorphanol

Lophophora (peyote)

Loprazolam

Lorazepam

Lormetazepam

Levomoramide

Lysergamide and N-alkyl derivatives of lysergamide other than lysergide

Lysergic acid

Mazindol

Mecloqualone (3-(2-Chlorophenyl)-2-methyl-4(3H)-quinazolinone)

Medazepam

Mefenorex (N-(3-Chloropropyl)-alpha-methylphenethylamine)

Mephobarbital

Meprobamate

Mescaline (3,4,5-Trimethoxyphenethylamine)

Mesocarb (3-(Alpha-methylphenethyl)-N-(phenylcarbamoyl)sydnone imine)

Metazocine

Methabarbital

Methadone

Methaqualone (2-Methyl-3-(2-methylphenyl)-4(3H)-quinazolinone)

Methcathinone

Methiopropamine

Methoxetamine

5-Methoxy alphamethyltryptamine (5-MeO-AMT)

4'-Methoxy-alpha-pyrrolidinopropiophenone (MOPPP)

N-(2-Methoxybenzyl)-2,5-dimethoxy-4-bromophenethylamine (25B-NBOMe)

N-(2-Methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe)

N-(2-Methoxybenzyl)-2,5-dimethoxy-3,4-dimethylphenethylamine (25G-NBOMe)

N-(2-Methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (25I-NBOMe)

5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT)

5-Methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)

5-Methoxy dimethyltryptamine

4-Methoxymethcathinone (Methedrone)

5-Methoxy-N-methyl-N-allyltryptamine (5-MeO-MALT)

5-Methoxy-3,4-methylenedioxyamphetamine (MMDA)

5-Methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MIPT)

4-Methoxyphenyl-(1-butyl-1H-indol-3-yl)-methanone (RCS-4 (C4))

2-(4-Methoxyphenyl)-1-(1-pentyl-1H-indol-3-yl)-ethanone (JWH-201)

2-(2-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-250)

2-(3-Methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone (JWH-302)

Methyl (2S, 4aR, 6aR, 7R, 9S, 10aS, 10bR)-9-Acetoxy-6a,10b-dimethyl-4,10-dioxo-dodecahydro-2-(3-furyl)-2H-naphtho{2,1-c]pyran-7-caboxylate (Salvinorin A)

4'-Methyl-alpha-pyrrolidinohexanophenone (MPHP)

4'-Methyl-alpha-pyrrolidinopropiophenone (MePPP)

N-Methyl-2-aminoindane

2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB)

2-Methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (Butylone)

2-Methylamino-1-phenyl-1-butan-1-one (Buphedrone)

2-(Methylamino)-1-phenylpentan-1-one (Pentedrone)

2-Methylamino-1-phenyl-1-propanone

2-(2-Methylaminopropyl)benzofuran (2-MAPB)

5-(2-Methylaminopropyl)benzofuran (5-MAPB)

6-(2-Methylaminopropyl)benzofuran (6-MAPB)

4-Methylaminorex

4-Methyl-N-benzylcathinone (Benzedrone)

Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3,3-dimethylbutanoate (MDMB CHMICA)

Methyl 2-(1-(cyclohexylmethyl)-indole-3-carboxamido)-3-methylbutanoate (MMB CHMICA)

Methyldesorphine

Methyldihydromorphine

3',4'-Methylenedioxy-alpha-pyrrolidinobutiophenone (MDPBP)

3',4'-Methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP)

5,6-Methylenedioxy-2-aminoindane (MDAI)

3,4-Methylenedioxyamphetamine (MDA)

3',4'-Methylenedioxy-N-benzylcathinone (BMDP)

1-(3,4-Methylenedioxy)-N,N-dimethylcathinone (Dimethylone)

3,4-Methylenedioxyethylamphetamine (MDEA)

1-(3,4-Methylenedioxy)ethylcathinone (Ethylone)

1-(3,4-Methylenedioxy)methcathinone (methylone)

3,4-Methylenedioxypyrovalerone (MDPV)

4-Methylethylcathinone (4-MEC)

3-Methylfentanyl

Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3,3-dimethylbutanoate (MDMB FUBINACA)

Methyl 2-(1-(4-fluorobenzyl)-indazole-3-carboxamido)-3-methylbutanoate (AMB FUBINACA)

Methyl 2-(1-(5-fluoropentyl)-indazole-3-carboxamido)-3-methylbutanoate (5-Fluoro AMB)

Methyl 2-(1-(5-fluoropentyl)-indole-3-carboxamido)-3-methylbutanoate (MMB-2201)

4-Methylmethcathinone

4-Methylmethylamphetamine (4-MMA)

2-Methyl-3-morpholino-1, 1-diphenylpropane carboxylic acid

Methylphenidate

Methylphenobarbital

1-[1-(4-Methylphenyl)cyclohexyl]piperidine

1-Methyl-4-phenylpiperidine-4-carboxylic acid

1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-adamantoyl)indole (AM-1248)

1-[(N-Methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (AM-2233)

1-[(N-Methylpiperidin-2-yl)methyl]-3-(4-methyl-1-naphthoyl)indole (MAM-1220)

1-[(N-Methylpiperidin-2-yl)methyl]-3-(1-naphthoyl)indole (AM-1220)

N-Methyl-3-piperidyl benzilate

4-Methylthioamphetamine (4-MTA)

3-Methylthiofentanyl

Methyprylon

Metodesnitazene

Metonitazene

Metopon

Midazolam

Mitragyne speciosa (kratom)

Moramide

Morpheridine

Morphine

Morphine methobromide

Morphine-N-oxide

1-[(2-(4-Morpholinyl)ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (A-796260)

1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)

Myrophine

Nabilone

Nalbuphine

Nalorphine

Naphthalen-1-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FDU-PB-22)

Naphthalen-1-yl 1-(5-fluoropentyl)-indole-3-carboxylate (NM-2201)

Naphthalen-1-yl 1-pentyl-indazole-3-carboxylate (SDB-005)

N-(1-Naphthalenyl)-1-pentyl-indole-3-carboxamide (NNEI)

Naphthoyl indole

Naphthylpyrovalerone (Naphyrone)

Nicocodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of nicocodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of nicocodine.

Nicodicodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of nicodicodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of nicodicodine.

Nicomorphine

Nimetazepam

Nitrazepam

Noracymethadol

6-Nor-6-allyl-lysergic acid diethylamide (AL-LAD)

Norcodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of norcodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of norcodeine.

Nordazepam

Norlevorphanol

Normethadone

Normorphine

Norpipanone

Opium

Oxazepam

Oxazolam

Oxycodone

Oxymorphone

Papaver bracteatum

Papaver orientale

Papaver somniferum other than the seed thereof which seed has been rendered sterile

Para-Fluorofentanyl

Parahexyl

Pemoline

Pentazocine

Pentobarbital

1-Pentyl-3-(1-adamantoyl)indole (AB-001)

1-Pentyl-3-(4-chloro-1-naphthoyl)indole (JWH-398)

1-Pentyl-3-(2-chlorophenylacetyl)indole (JWH-203)

1-Pentyl-3-(4-ethyl-1-naphthoyl)indole (JWH-210)

(1-Pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144)

1-Pentyl-3-[(4-methoxy)-benzoyl]indole (RCS-4)

1-Pentyl-3-(2-methoxybenzoyl)indole (RCS-4 (2-methoxy isomer))

1-Pentyl-3-(4-methoxy-1-naphthoyl)indole (JWH-081)

1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122)

1-Pentyl-3-(1-naphthoyl)indole (JWH-018)

Pethidine

Phenadoxone

Phenampromide

Phenazepam

Phenazocine

Phendimetrazine

Phenmetrazine

Phenobarbital

Phenomorphan

Phenoperidine

Phentermine (alpha,alpha-Dimethylphenethylamine)

1-(1-Phenylcyclohexyl)pyrrolidine (PCPy)

Phenylmethylbarbituric Acid

1-[1-(Phenylmethyl)cyclohexyl]piperidine

4-Phenylpiperidine-4-carboxylic acid ethyl ester

Phenylpiracetam

1-Phenyl-N-propylcyclohexanamine

Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine.

Phthalimidopropiophenone

Piminodine

Pinazepam

Pipradol

Piritramide

Pravadoline (WIN 48098)

Prazepam

Probarbital

Proheptazine

Propallylonal

Properidine

Propiram

Propylhexedrine (1-cyclohexyl-2-methylaminopropane)

1-Propyl-2-methyl-3-(1-naphthoyl)indole (JWH-015)

N-Propyl-3,4-methylenedioxyamphetamine (MDPR)

Protonitazene

Psilocin (4-Hydroxy-N,N-dimethyltryptamine)

Psilocybin (O-Phosphoryl-4-hydroxy-N,N-dimethyltryptamine)

Pyrovalerone

N-Pyrrolidino protonitazene (Protonitazepyne)

Quazepam

Quinolin-8-yl 1-(cyclohexylmethyl)-indole-3-carboxylate (BB-22)

Quinolin-8-yl 1-(4-fluorobenzyl)-indole-3-carboxylate (FUB-PB-22)

Quinolin-8-yl 1-(5-fluoropentyl)-indazole-3-carboxylate (5-Fluoro NPB-22)

Quinolin-8-yl 1-(5-fluoropentyl)-1-indole-3-carboxamide

Quinolin-8-yl 1-(5-fluoropentyl)-indole-3-carboxylate (5-Fluoro PB-22)

Quinolin-8-yl 4-methyl-3-(1-piperidinylsulfonyl)benzoate (QMPSB)

Quinolin-8-yl 1-pentyl-1-indazole-3-carboxamide (THJ)

Quinolin-8-yl 1-pentyl-indazole-3-carboxylate (NPB-22)

Quinolin-8-yl 1-pentyl-indole-3-carboxylate (PB-22)

Racemethorphan

Racemoramide

Racemorphan

Remifentanil

Reproterol

Salbutamol other than in metered aerosols or dry powder or capsules of dry powder for inhalation

Salvia divinorum

Secobarbital

Sigmodal

Somatotropin

Sufentanil

Talbutal

Temazepam

Terbutaline, other than in metered aerosols for inhalation

Testolactone

Tetrahydrocannabinols including their alkyl homologues other than where separately specified; and their corresponding carboxylic acids

2,2,3,3-Tetramethyl-N'-(2-oxo-(1-(5-fluoropentyl)indolin-3-yliden))-cyclopropanecarbohydrazide

Tetrazepam

Thebacon

Thebaine

Thialbarbital

Thiamylal

1-(1-(2-Thienyl)cyclohexyl)piperidine (TCP)

Thiobarbituric Acid

Thiofentanyl

Thiopental

Tilidine

Triazolam

1-(3-Trifluoromethylphenyl) piperazine (TFMPP)

Trimeperidine

2,4,5-Trimethoxyamphetamine

3,4,5-Trimethoxyamphetamine

Vinbarbital

Vinylbital

Zeranol

Zipeprol (1-(2-Methoxy-2-phenylethyl))-4-(2-hydroxy-3-methoxy-3- phenylpropyl) piperazine

Zolazapam

Zolpidem

sch 2 (prev 1986 Act No. 36sch 2) amd 1987 Act No. 53s 11; 1989 Act No. 34s 22; 1996 Act No. 49s 16 reloc 1996 Act No. 49s 21 amd 1997 SL No. 303s 3; 1997 SL No. 459s 4; 1999 SL No. 41s 3; 2001 SL No. 174s 5; 2001 SL No. 249s 3; 2002 SL No. 255s 7(1); 2002 SL No. 368s 5; 2003 SL No. 374s 3; 2005 SL No. 7s 3 sub 2008 Act No. 4s 41 amd 2009 SL No. 99s 6; 2011 SL No. 168s 3; 2011 SL No. 222s 3; 2013 SL No. 41s 4; 2013 SL No. 266s 3; 2014 Act No. 42s 24; 2017 SL No. 41s 3; 2018 SL No. 50s 3; 2024 SL No. 163s 3 Schedule 3 Specified quantities for particular dangerous drugs sections 4A, 8, 9, 125 and 134 of the Act sch 2A ins 2000 Act No. 28s 26sch amd 2002 SL No. 255s 7(1); 2002 SL No. 368s 6 om 2008 Act No. 4s 42 Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 2.0g Barbituric Acid and any 5,5 disubstituted derivatives of barbituric acid whether or not further substituted at position 1 of the ring 50.0g 4-Bromo-2,5-dimethoxyamphetamine 0.5g 4-Bromo-2,5-dimethoxyphenethylamine 2.0g Cannabis 500.0g or, if the dangerous drug consists of plants the aggregate weight of which is less than 500.0g, 100 plants Cocaine 2.0g Codeine 10.0g N,N-Diethyltryptamine 2.0g 2,5-Dimethoxy-4-Ethylamphetamine (DOET) 2.0g 2,5-Dimethoxy-4-Methylamphetamine 2.0g N,N-Dimethyltryptamine 2.0g Fenethylline 2.0g Fentanyl 0.01g Gamma hydroxybutyric acid 2.0g Heroin 2.0g Hydromorphone 2.0g Lysergide 0.004g Methadone 2.0g Methcathinone 2.0g 5-Methoxy-3,4-Methylenedioxyamphetamine (MMDA) 2.0g 2-Methylamino-1-(3,4-methylenedioxyphenyl) butane (MBDB) 2.0g 4-Methylaminorex 2.0g Methylamphetamine 2.0g 3,4-Methylenedioxyamphetamine (MDA) 2.0g 3,4-Methylenedioxyethylamphetamine (MDEA) 2.0g 3,4-Methylenedioxymethamphetamine (MDMA) 2.0g 4-Methylthioamphetamine (4-MTA) 2.0g Moramide 2.0g Morphine 2.0g Opium 20.0g Paramethoxyamphetamine (PMA) 2.0g Paramethoxymethamphetamine (PMMA) 2.0g Pethidine 10.0g Phencyclidine 0.5g Psilocin 0.10g Psilocybin 0.10g Tetrahydrocannabinols including their alkyl homologues except where separately specified; and their corresponding carboxylic acids 2.0g 3,4,5-Trimethoxyamphetamine (TMA) 2.0g

Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 50.0g

sch 3 (prev 1986 Act No. 36sch 3) amd 1987 Act No. 53s 12; 1989 Act No. 34s 23 sub 1990 Act No. 88s 3sch amd 1996 Act No. 49s 17 reloc 1996 Act No. 49s 21 amd 1997 SL No. 303s 4; 1997 SL No. 459s 5; 1999 SL No. 41s 4; 2001 SL No. 249s 4; 2002 SL No. 255s 7(1)–(2); 2002 SL No. 368s 7; 2008 Act No. 4s 43; 2009 SL No. 99s 7; 2013 SL No. 41s 5; 2014 Act No. 42s 25; 2018 SL No. 50s 4 Schedule 4 Specified quantities for particular dangerous drugs sections 4A, 8, 9 and 134 of the Act Part 1 Quantities of non-steroid drugs Dangerous drug Quantity of dangerous drug Amphetamine 200.0g Cocaine 200.0g Heroin 200.0g Lysergide 0.4g Methylamphetamine 200.0g 3,4-Methylenedioxymethamphetamine (MDMA) 200.0g Paramethoxyamphetamine (PMA) 200.0g Paramethoxymethamphetamine (PMMA) 200.0g Phencyclidine 50.0g

Part 2 Quantities of steroid drugs Dangerous drug Whole weight of dangerous drug a dangerous drug mentioned in schedule 1, part 2 5,000.0g

sch 4 (prev 1986 Act No. 36sch 4) amd 1996 Act No. 49s 18 reloc 1996 Act No. 49s 21 amd 1997 SL No. 459s 6; 2001 SL No. 174s 6; 2002 SL No. 255s 7(1); 2008 Act No. 4s 44; 2008 SL No. 144s 4; 2009 SL No. 99s 8; 2013 SL No. 41s 6; 2014 Act No. 42s 26 Schedule 5 Dangerous drugs sections 4A, 124 and 134 of the Act

Alprazolam

Bromazepam

Brotizolam

Camazepam

Chlordiazepoxide

Clobazam

Clonazepam

Clorazepate

Clotiazepam

Cloxazolam

Delorazepam

Diazepam

Difenoxin other than in preparations containing 0.5mg or less of difenoxin and a quantity of atropine sulphate equivalent to not less than 5% of the dose of difenoxin per dosage unit

Dihydrocodeine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of dihydrocodeine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of dihydrocodeine.

Diphenoxylate other than in preparations containing 2.5mg or less of diphenoxylate and a quantity of atropine sulphate equivalent to not less than 1% of the dose of diphenoxylate per dosage unit

Estazolam

Ethyl Loflazepate

Fludiazepam

Flurazepam

Halazepam

Haloxazolam

Ketazolam

Loprazolam

Lorazepam

Lormetazepam

Medazepam

Midazolam

Nimetazepam

Nitrazepam

Nordazepam

Oxazepam

Oxazolam

Pholcodine other than where it is compounded with 1 or more other medicaments in such a way that it can not be readily extracted and where it is contained—

(a) in divided preparations containing 100mg or less of pholcodine per dosage unit; or

(b) in undivided preparations containing 2.5% or less of pholcodine.

Pinazepam

Prazepam

Quazepam

Temazepam

Tetrazepam

Triazolam

Zolazapam

sch 5 (prev 1986 Act No. 36sch 5) amd 1987 Act No. 53s 13; 1996 Act No. 49s 19 reloc 1996 Act No. 49s 21 amd 1997 SL No. 459s 7; 2002 SL No. 255s 7(1), (3) sub 2008 Act No. 4s 45 amd 2009 SL No. 99s 8 Schedule 6 Controlled substances sections 4, definition controlled substance, and 134 of the Act Substance Alternative name Acetaldehyde Acetic anhydride N-Acetylanthranilic acid 2-Acetamidobenzoic acid N-Acetylephedrine N-Acetylpseudoephedrine Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 4-Allylpyrocatechol Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime Alpha-methyl-3,4- methylenedioxyphenylpropanamide Alpha-methylstyrene Alpha-phenylacetoacetamide (APAA) Alpha-phenylacetoacetonitrile (APAAN) Ammonium formate Anethole 4-Anilino-N-phenethylpiperidine (ANPP) 4-Anilinopiperidine Anthranilic acid 2-Aminobenzoic acid Benzaldehyde 1,3-Benzodioxole Benzyl bromide α-Bromotoluene Benzyl chloride α-Chlorotoluene Benzyl cyanide 1-Benzyl-4-piperidone Boron tribromide Bromobenzene Phenylbromide 5-Bromo-1,3-benzodioxole 3,4-Methylenedioxybromobenzene Bromo safrole 1,4-Butanediol Tetramethylene glycol Calcium metal Chloroephedrine 1-Chlorophenyl-2-aminopropane Chloropseudoephedrine Chromic acid Chromium trioxide Chromium (VI) oxide Ephedrine Ergocristine Ergometrine Ergonovine Ergotamine Ethanamine Monoethylamine Ethyl alpha-phenylacetoacetate (EAPA) N-Ethylephedrine Ethyl phenylacetate Benzeneacetic acid, ethyl ester N-Ethylpseudoephedrine Eugenol Formaldehyde Formamide Gamma-Aminobutyric acid (GABA) 4-Aminobutanoic acid Helional Hydriodic acid Hydrogen iodide solution Hydrobromic acid Hydrogen bromide solution 4-Hydroxybutanal 4-Hydroxybutyraldehyde 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 1-Hydroxycyclopentyl-(o-chlorophenyl)-ketone N-methylimine 4-Hydroxypentanoic acid Gamma-Hydroxyvaleric acid 4-Hydroxypentanoic acid lactone Gamma-valerolactone 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol Hypophosphorous acid Phosphinic acid Iodine Isosafrole 5-(1-Propenyl)-1,3-benzodioxole Lithium aluminium hydride Lithium metal Magnesium metal Mandelic acid Alpha-Hydroxyphenylacetic acid Mercuric chloride Mercury bichloride or Mercury (II) chloride Mercury metal N-Methylalanine Methyl alpha-phenylacetoacetate (MAPA) Methylamine Aminomethane or Monomethylamine Methylammonium salts 3,4-Methylenedioxphenylacetic acid 3,4-Methylenedioxyphenylacetonitrile 3,4-Methylenedioxyphenyl-2-nitropropene 3,4-Methylenedioxyphenyl-2-propanone N-Methylephedrine N-Methylformamide Methyl 3-[3’,4’-(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG) Methyl phenylacetate Benzeneacetic acid, methyl ester Methyl 3-phenyl-2-methyl glycidate P2P methyl glycidic acid, methyl ester N-Methylpseudoephedrine Nitroethane Nitromethane Norpseudoephedrine Palladium Paramethoxyphenyl-2-propanone N-(2-Phenethyl)-4-piperidinone (NPP) Phenylacetamide Phenylacetic acid Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile L-Phenylacetylcarbinol L-PAC or 1-Hydroxy-1-phenyl-2-propanone Phenylacetyl chloride 1-Phenyl-2-bromopropane 1-Phenyl-2-chloropropane 1-Phenyl-2-iodopropane 1-Phenyl-2-methylaminopropane 1-Phenyl-2-nitropropene 4-Phenyl-3-oxobutanoic acid 4-Phenylacetoacetic acid 2-Phenylpropanal Hydratropaldehyde 1-Phenyl-1,2-propanedione Benzoyl methyl ketone 1-Phenyl-2-propanol Phenylpropanolamine Norephedrine 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 1-Phenyl-2-propanone bisulphite 1-Phenyl-2-propanone oxime Phosphorous acid Phosphonic Acid Phosphorus (red or white) Piperidine 4-Piperidone Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde Platinum metal Potassium metal Propionic anhydride Pseudoephedrine Pyridine 2-Pyrrolidone Gamma-butyrolactam Raney nickel Safrole 5-(2-Propenyl)-1,3-benzodioxide Sassafras oil Sodium bis(2-methoxyethoxy) aluminium hydride Sodium borohydride Sodium cyanoborohydride Sodium metal Sodium 2-methyl-3-(3,4-methylenedioxy)phenyl-glycidate Sodium 2-methyl-3-phenyl glycidate Thionyl chloride Thorium P-Tosyl 3,4-methylenedioxyphenyl-2-propanol P-Tosyl MDP2Pol P-Tosyl phenyl-2-propanol P-Tosyl P2Pol Trans-beta-methylstyrene

sch 6 (prev 1986 Act No. 36sch 6) ins 1995 Act No. 18s 8 amd 1996 Act No. 49s 20 reloc 1996 Act No. 49s 21 amd 1997 SL No. 459s 8; 2002 SL No. 255s 7(1) sub 2006 SL No. 71s 5 amd 2009 SL No. 99s 9; 2018 SL No. 169s 4; 2026 SL No. 39s 3 Schedule 7 Conditions for particular persons authorised under part 4 section 10 (2) sch 7 hdg ins 1998 SL No. 348s 5 1 DPI researcher A DPI researcher must—

(a) keep class A research cannabis plants the researcher is growing securely locked in a glasshouse; and

(b) grow class B research cannabis plants in an area that is fenced to delineate the area under production; and

(c) if the chief executive requires the researcher to erect signs indicating the presence of class B research cannabis at a fenced area, ensure the signs are erected as required by the chief executive; and

(d) keep industrial cannabis seed and class A and class B research cannabis seed in the researcher’s possession or under the researcher’s control locked in a secure place when not otherwise required—

(i) for use for planting; or

(ii) to be supplied to another person; and

(e) keep a register that includes the following information—

(i) the varieties or strains of cannabis plants and cannabis seed under the researcher’s control;

(ii) the source, quantity and delivery details for cannabis seed and plant varieties the researcher receives;

(iii) how, when and from whom the researcher received cannabis plants and seed delivered to the researcher;

(iv) if a carrier delivered the cannabis plants or seed to the researcher, the name of the person who delivered the plants or seed;

(v) if a researcher engages a carrier to deliver cannabis plants or seed to someone else—

(A) the name of the person to whom the plants or seed were given for delivery; and

(B) the name of the person to whom it is intended the plants or seed be supplied by the researcher.

sch 7 s 1 prev sch 1 s 1 ins 1998 SL No. 348s 5 sub 2002 SL No. 255s 8 amd 2009 SL No. 99s 10; 2018 Act No. 5s 133 om 2018 Act No. 5s 151(1) pres sch 1 s 1 (prev sch 1 s 2) ins 1998 SL No. 348s 5 sub 2002 SL No. 255s 8 renum 2018 Act No. 5s 151(4) 2 Inspector An inspector who possesses industrial cannabis plants or seed or class A or class B research cannabis plants or seed for supplying them to someone else under part 4 must keep the plants or seed in a secure place until the inspector supplies them to the person. sch 7 s 2 (prev sch 7 s 3) ins 1998 SL No. 348s 5 sub 2002 SL No. 255s 8 renum 2018 Act No. 5s 151(4) 3 Analyst (1) This section applies if an analyst is engaged or employed to analyse a substance to determine its THC concentration. (2) The analyst must analyse the substance in a NATA accredited laboratory. (3) The analyst must keep standard THC material in a securely locked place other than when the analyst is using the material in analysing the substance to determine its THC concentration. (4) The analyst must keep the substance in a securely locked place other than when the analyst is analysing the substance. (5) In this section— substance means a substance the analyst reasonably believes to be any of the following—

(a) industrial cannabis plants;

(b) class A or class B research cannabis plants;

sch 7 s 3 (prev sch 7 s 5) ins 2002 SL No. 255s 8 amd 2018 Act No. 5s 151(2)–(3) renum 2018 Act No. 5s 151(4) 4 sch 7 s 4 ins 1998 SL No. 348s 5 amd 1999 SL No. 235s 3 sub 2002 SL No. 255s 8 amd 2018 Act No. 5s 133 om 2018 Act No. 5s 151(1) sch 7 sub 2002 SL No. 255s 8 Schedule 8 Licence conditions section 29 (1) Part 1 General conditions

1 A licensee must keep cannabis seed in the licensee’s possession in a securely locked place, other than when the licensee uses the seed for a purpose that is authorised under the licensee’s licence.

2 As soon as reasonably practicable after a licensee receives a package containing cannabis plants or seed that appears to have been tampered with, the licensee must inform an inspector or a police officer that the package appears to have been tampered with.

3 A licensee who proposes to supply industrial cannabis seed for sale by wholesale or retail must ensure—

(a) if the seed is cannabis seed harvested from an industrial cannabis plant—the seed is labelled so as to describe the seed as cannabis seed harvested from an industrial cannabis plant; or

(b) if the seed is to be supplied as planting seed—the seed is labelled with the required particulars.

Note— See section 27C for additional labelling requirements. Part 2 Particular conditions for researcher licences

4 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the researcher that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a concentration of THC in their leaves and flowering heads of 3% or more.

5 A researcher, whose licence is subject to a condition prohibiting the researcher from dealing with class A research cannabis plants and seed, must ensure, as far as practicable, that cannabis seed supplied to the researcher by a person in another State or a foreign country is certified as seed that, if grown, will produce cannabis plants with a THC concentration in their leaves and flowering heads of less than 3%.

6 A researcher must carry out activities under the researcher’s licence in accordance with the approved research plan for the licence.

Part 3 Particular conditions for grower licences

7 A grower must allow an inspector to destroy, or supervise the destruction of, cannabis plants in the possession of the grower that have been found, by an analyst conducting a laboratory analysis of a random sample of the leaves and flowering heads of the plants, to have a THC concentration in their leaves and flowering heads of more than 1%.

Part 4 Particular conditions for seed handler licences

8 A seed handler must—

(a) ensure all industrial cannabis seed in the possession of the seed handler is labelled to state—

(i) if the seed is cannabis seed harvested from an industrial cannabis plant—that fact; or

(ii) if the seed is intended to be used or supplied as planting seed—the required particulars; and

Note— See section 27C for additional labelling requirements.

(b) pack all industrial cannabis seed to be delivered to someone else by a carrier in a way that ensures, as far as reasonably practicable, seed can not escape from the packaging or be accidentally released or tampered with.

sch 8 ins 1998 SL No. 348s 5 sub 1999 SL No. 235s 4; 2000 SL No. 234s 3; 2002 SL No. 255s 8 amd 2018 Act No. 5s 134 sub 2018 Act No. 5s 152 Schedule 8A Gross weight of relevant substances for ss 9A, 9B, 9C and 9D of Act sections 9A, 9B, 9C, 9D and 134 of the Act Part 1 Substances that include their salts, derivatives and stereo-isomers 1 In this part, a reference to a substance includes a reference to—

(a) a salt, derivative or stereo-isomer of the substance; and

(b) a salt of a derivative or stereo-isomer of the substance.

Substance Alternative name Gross weight Acetaldehyde 0.1g N-Acetylanthranilic acid 2-Acetamidobenzoic acid 0.1g N-Acetylephedrine 0.1g N-Acetylpseudoephedrine 0.1g Allylbenzene 3-Phenyl-1-propene or 2-propenyl benzene 0.1g 4-Allylpyrocatechol 0.1g Alpha-methyl-3,4- methylenedioxyphenylpropanaldoxime 0.1g Alpha-methyl-3,4- methylenedioxyphenylpropanamide 0.1g Alpha-methylstyrene 0.1g Alpha-phenylacetoacetamide (APAA) 0.1g Alpha-phenylacetoacetonitrile (APAAN) 0.1g Ammonium formate 0.1g Anethole 0.1g 4-Anilino-N-phenethylpiperidine (ANPP) 0.1g 4-Anilinopiperidine 0.1g Anthranilic acid 2-Aminobenzoic acid 0.1g Benzaldehyde 0.1g 1,3-Benzodioxole 0.1g Benzyl bromide α-Bromotoluene 0.1g Benzyl chloride α-Chlorotoluene 0.1g Benzyl cyanide 0.1g 1-Benzyl-4-piperidone 0.1g Boron tribromide 0.1g Bromobenzene Phenylbromide 0.1g 5-Bromo-1,3-benzodioxole 3,4-Methylenedioxybromobenzene 0.1g Bromo safrole 0.1g 1,4-Butanediol Tetramethylene glycol 0.1g Chloroephedrine 0.1g 1-Chlorophenyl-2-aminopropane 0.1g Chloropseudoephedrine 0.1g Chromic acid 0.1g Chromium trioxide Chromium (VI) oxide 0.1g Ephedrine 0.1g Ergocristine 0.1g Ergometrine Ergonovine 0.1g Ergotamine 0.1g Ethanamine Monoethylamine 0.1g Ethyl alpha-phenylacetoacetate (EAPA) 0.1g N-Ethylephedrine 0.1g Ethyl phenylacetate Benzeneacetic acid, ethyl ester 0.1g N-Ethylpseudoephedrine 0.1g Eugenol 0.1g Formaldehyde 0.1g Formamide 0.1g Gamma-Aminobutyric acid (GABA) 4-Aminobutanoic acid 0.1g Helional 0.1g 4-Hydroxybutanal 4-Hydroxybutyraldehyde 0.1g 4-Hydroxybutanoic acid lactone Gamma-butyrolactone 0.1g 4-Hydroxybutanoic acid nitrile 4-Hydroxybutyronitrile 0.1g 1-Hydroxycyclopentyl-(o-chlorophenyl)-ketone N-methylimine 0.1g 4-Hydroxypentanoic acid Gamma-Hydroxyvaleric acid 0.1g 4-Hydroxypentanoic acid lactone Gamma-valerolactone 0.1g 2-Hydroxytetrahydrofuran Tetrahydro-2-furanol 0.1g Hypophosphorous acid Phosphinic acid 0.1g Isosafrole 5-(1-Propenyl)-1,3-benzodioxole 0.1g Lithium aluminium hydride 0.1g Mandelic acid Alpha-Hydroxyphenylacetic acid 0.1g Mercuric chloride Mercury bichloride or Mercury (II) chloride 0.1g N-Methylalanine 0.1g Methyl alpha-phenylacetoacetate (MAPA) 0.1g Methylamine Aminomethane or Monomethylamine 0.1g Methylammonium salts 0.1g 3,4-Methylenedioxphenylacetic acid 0.1g 3,4-Methylenedioxyphenylacetonitrile 0.1g 3,4-Methylenedioxyphenyl-2-nitropropene 0.1g 3,4-Methylenedioxyphenyl- 2-propanone 0.1g N-Methylephedrine 0.1g N-Methylformamide 0.1g Methyl 3-[3’,4’-(methylenedioxy)phenyl]-2-methyl glycidate (MMDMG) 0.1g Methyl phenylacetate Benzeneacetic acid, methyl ester 0.1g Methyl 3-phenyl-2-methyl glycidate P2P methyl glycidic acid, methyl ester 0.1g N-Methylpseudoephedrine 0.1g Nitroethane 0.1g Nitromethane 0.1g Norpseudoephedrine 0.1g Palladium 0.1g Paramethoxyphenyl-2-propanone 0.1g N-(2-Phenethyl)-4-piperidinone (NPP) 0.1g Phenylacetamide 0.1g Phenylacetic acid 0.1g Phenylacetonitrile Benzeneacetonitrile, Benzyl cyanide or Benzyl nitrile 0.1g L-Phenylacetylcarbinol L-PAC or 1-Hydroxy-1-phenyl-2-propanone 0.1g Phenylacetyl chloride 0.1g 1-Phenyl-2-bromopropane 0.1g 1-Phenyl-2-chloropropane 0.1g 1-Phenyl-2-iodopropane 0.1g 1-Phenyl-2-methylaminopropane 0.1g 1-Phenyl-2-nitropropene 0.1g 4-Phenyl-3-oxobutanoic acid 4-Phenylacetoacetic acid 0.1g 2-Phenylpropanal Hydratropaldehyde 0.1g 1-Phenyl-1,2-propanedione Benzoyl methyl ketone 0.1g 1-Phenyl-2-propanol 0.1g Phenylpropanolamine Norephedrine 0.1g 1-Phenyl-1-propanone Phenyl ethyl ketone or Propiophenone 0.1g 1-Phenyl-2-propanone Benzyl methyl ketone or Phenylacetone 0.1g 1-Phenyl-2-propanone bisulphite 0.1g 1-Phenyl-2-propanone oxime 0.1g Piperidine 0.1g 4-Piperidone 0.1g Piperonal Heliotropine or 3,4-Methylenedioxybenzaldehyde 0.1g Propionic anhydride 0.1g Pseudoephedrine 50g or 1L Pyridine 0.1g 2-Pyrrolidone Gamma-butyrolactam 0.1g Raney nickel 0.1g Safrole 5-(2-Propenyl)-1,3-benzodioxide 0.1g Sassafras oil 0.1g Sodium bis(2-methoxyethoxy) aluminium hydride 0.1g Sodium borohydride 0.1g Sodium cyanoborohydride 0.1g Sodium 2-methyl-3-(3,4-methylenedioxy)phenyl-glycidate 0.1g Sodium 2-methyl-3-phenyl glycidate 0.1g Thionyl chloride 0.1g Thorium 0.1g P-Tosyl 3,4-methylenedioxyphenyl-2-propanol P-Tosyl MDP2Pol 0.1g P-Tosyl phenyl-2-propanol P-Tosyl P2Pol 0.1g Trans-beta-methylstyrene 0.1g

Part 2 Substances that do not include their salts, derivatives and stereo-isomers 2 In this part, a reference to a substance does not include a reference to—

(a) a salt, derivative or stereo-isomer of the substance; and

(b) a salt of a derivative or stereo-isomer of the substance.

Substance Alternative name Gross weight Acetic anhydride 0.1g Calcium metal 0.1g Hydriodic acid Hydrogen iodide solution 0.1g Hydrobromic acid Hydrogen bromide solution 0.1g Iodine 0.1g Lithium metal 25g Magnesium metal 0.1g Mercury metal 0.1g Phosphorous acid Phosphonic Acid 0.1g Phosphorus (red or white) 0.1g Platinum metal 0.1g Potassium metal 0.1g Sodium metal 0.1g

sch 8A ins 2006 SL No. 71s 6 amd 2008 Act No. 4s 46; 2013 Act No. 14s 50; 2018 SL No. 169s 5; amd 2026 SL No. 39s 4 Schedule 8B Things specified for ss 9A, 9B, 9C and 9D, and prescribed for s 134, of Act sections 9A, 9B, 9C, 9D and 134 of the Act

1 hydrogen sulfide gas cylinder

2 hydrogen chloride gas cylinder

3 hydrogen gas cylinder

4 ammonia gas cylinder

5 condenser

6 distillation head

7 heating mantle

8 manual or mechanical pill press, including a pill press under repair, a modification of a pill press and parts for a pill press

9 reaction vessel, including a reaction vessel under repair or a modification of a reaction vessel

10 rotary evaporator

11 splash head, including a splash head under repair or parts for a splash head

sch 8B ins 2006 SL No. 71s 6 amd 2008 Act No. 4s 47; 2009 SL No. 99s 11; 2013 Act No. 14s 51; 2018 SL No. 169s 6 Schedule 8C Prohibited combinations of items sections 10B and 134 of the Act

1 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) hypophosphorous acid; and

2 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) hydriodic acid; and

3 A combination consisting of substances that are or contain—

(a) pseudoephedrine or its salts; and

(b) lithium metal; and

sch 8C ins 2006 SL No. 71s 6 Schedule 8D Relevant dangerous drugs sections 131 and 134 of the Act

amphetamine

methylamphetamine

sch 8D ins 2006 SL No. 71s 6 Schedule 8E Fees sections 28 and 28A Fee units 1 Application fee for a researcher licence (Act, s 54(2)(a)) 1,942.95 2 Application fee for a grower licence (Act, s 54(2)(a)) 1,304.95 3 Application fee for a seed handler licence (Act, s 54(2)(a)) 435.65 4 Licence renewal fee for a researcher licence (Act, s 65(2)(d)(i)) 1,572.85 5 Licence renewal fee for a grower licence (Act, s 65(2)(d)(i)) 1,059.95 6 Licence renewal fee for a seed handler licence (Act, s 65(2)(d)(i)) 435.65 7 Application fee for amendment of a licence or a condition of a licence (Act, s 70(2)) 294.95 8 Monitoring of an activity performed under a relevant authority, for each hour involved (Act, s 110G(1)) 322.05 Notes—

1 See section 28A(2) in relation to a fee for part of an hour.

2 See section 28A(3) and (4) in relation to the fee for an inspector’s travel and the cost of analysis of a sample of cannabis for monitoring an activity.

sch 8E ins 2022 SL No. 6s 4 amd 2022 SL No. 52s 17 Schedule 9 Dictionary section 2 analyst means a person who is authorised under the Medicines and Poisons Act 2019 to use standard THC material to calibrate an analytical instrument used for analysing a substance to determine its THC concentration. sch 9 def analyst sub 2021 SL No. 141s 93sch 8 approved research plan, for a researcher licence, means a research plan that forms part of the licence under section 63(4) of the Act as amended in accordance with the Act. sch 9 def approved research plan ins 2018 Act No. 5s 153(2) carrier means a person who carries on a business of transporting a thing for delivery to the person to whom it is consigned, whether in Queensland or elsewhere, and whether the thing is transported by air, rail, road or sea. condenser means a cooling device for converting gases or vapours to liquid or solid form. sch 9 def condenser ins 2006 SL No. 71s 7 consigned includes addressed. consigned cannabis means any of the following—

(a) industrial cannabis plants;

(b) industrial cannabis seed;

(d) class B research cannabis;

(e) processed cannabis.

distillation head means an apparatus that—

(a) fits on top of a reaction vessel or a vessel that serves the same purpose as a reaction vessel; and

(b) connects to a condenser; and

sch 9 def distillation head ins 2006 SL No. 71s 7 DPI researcher means a public service officer—

(a) who is employed in the department within which the Biosecurity Act 2014 is administered; and

(b) whose duties include plant breeding; and

sch 9 def DPI researcher amd 2016 SL No. 75s 129sch 12 gas cylinder means a cylinder or other thing that—

(a) is used for storing gas in any form; and

(b) has a storage capacity of less than 1 tonne.

sch 9 def gas cylinder ins 2018 SL No. 169s 7 heating mantle means a device designed or adapted to heat a reaction vessel or a vessel that serves the same purpose as a reaction vessel. sch 9 def heating mantle ins 2006 SL No. 71s 7 NATA means the National Association of Testing Authorities, Australia ABN 59 004 379 748. sch 9 def NATA ins 2018 Act No. 5s 153(2) NATA accredited laboratory means a laboratory whose functions and operations are accredited by NATA for competence to undertake drug analysis. sch 9 def NATA accredited laboratory ins 2018 Act No. 5s 153(2) occupier’s notice ... sch 9 def occupier’s notice reloc 1998 SL No. 348s 3(1) om 2002 SL No. 255s 8 recipient licensee, in relation to cannabis seed originating in another State or another country, means the licensee who first takes possession of the seed after it enters the State. sch 9 def recipient licensee ins 2018 Act No. 5s 153(2) record of proceedings ... sch 9 def record of proceedings reloc 1998 SL No. 348s 3(1) om 2002 SL No. 255s 8 required particulars means—

(a) a report number, or other identifying information, for the report containing the results mentioned in section 11(2)(a)(ii), (3)(a)(ii) or (4)(a)(ii); and

(b) the words ‘planting seed’; and

(c) the words ‘This seed was harvested from a cannabis plant with a THC concentration in the plant’s leaves and flowering heads, of not more than 0.5%’; and

(d) for cannabis seed originating in the State—the name and licence number of the grower who produced the seed; and

(e) for cannabis seed originating in another State or another country—the name of—

(i) the State or other country; and

(ii) the recipient licensee.

sch 9 def required particulars ins 2018 Act No. 5s 153(2) search warrant ... sch 9 def search warrant reloc 1998 SL No. 348s 3(1) om 2002 SL No. 255s 8 seed supplier ... sch 9 def seed supplier om 2018 Act No. 5s 153(1) splash head means an apparatus that fits between a reaction vessel, or a vessel that serves the same purpose as a reaction vessel, and a condenser and stops a heated substance contaminating the distillate. sch 9 def splash head ins 2006 SL No. 71s 7 standard THC material means THC of a known purity. supply—

(a) for part 3, see section 43A of the Act; or

(b) for part 4, does not include administer.

sch 9 ins 1998 SL No. 348s 5 sub 2002 SL No. 255s 8